Rasp Wealth Solutions LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 23.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,286 shares of the company’s stock after selling 39,457 shares during the period. Eli Lilly and Company makes up approximately 59.2% of Rasp Wealth Solutions LLC’s portfolio, making the stock its biggest holding. Rasp Wealth Solutions LLC’s holdings in Eli Lilly and Company were worth $150,752,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Marshall & Sterling Wealth Advisors Inc. grew its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares during the period. Torren Management LLC raised its holdings in shares of Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares during the period. AlphaCentric Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $42,000. Foresight Capital Management Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at about $49,000. Finally, Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $64,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Eli Lilly and Company Stock Up 1.2%
NYSE LLY traded up $16.77 during trading hours on Friday, reaching $1,444.05. 2,080,606 shares of the company traded hands, compared to its average volume of 3,003,279. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,460.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $1.36 trillion, a PE ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. The company has a 50 day moving average of $1,242.25 and a two-hundred day moving average of $1,110.30.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.02 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.
Insider Activity at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
More Eli Lilly and Company News
Here’s some of the latest news about LLY:
- Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
- Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
- Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on LLY shares. Royal Bank Of Canada increased their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. UBS Group increased their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. Finally, Argus boosted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.
Get Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
- Five stocks we like better than Eli Lilly and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
